POSB320 Matching-Adjusted Indirect Comparison of Guselkumab Versus Risankizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Change in Baseline PASI from Week 4-40
Abstract
Authors
C Sanyal A Situ S Alulis F Hassan S Peterson J Lee